trending Market Intelligence /marketintelligence/en/news-insights/trending/wwder_nbepilq0-wb-xhbw2 content esgSubNav
In This List

Lilly's Taltz succeeds in phase 3b trial for inflammatory skin disease

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Lilly's Taltz succeeds in phase 3b trial for inflammatory skin disease

Eli Lilly and Co. said its drug Taltz reduced sexual difficulties caused by genital psoriasis in a phase 3b trial.

Psoriasis is an inflammatory, autoimmune condition that can affect the skin anywhere on the body.

The treatment was superior to placebo in the first week for limitations on frequency of sexual activity due to genital psoriasis, and week two for the sexual difficulties caused by skin symptoms.

Taltz, which is also known as ixekizumab, is approved for treating adult patients with active psoriatic arthritis as well as moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.